[Corrigendum] miR‑505 suppresses prostate cancer progression by targeting NRCAM
Affiliations: Guangdong Provincial Institute of Nephrology, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of Urology, Nanhua Affiliated Hospital, University of South China, Hengyang, Hunan 421001, P.R. China, Reproductive Medicine Centre, Huizhou Central People's Hospital, Guangdong Medical University, Huizhou, Guangdong 516001, P.R. China, Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China, Department of Botany and Plant Sciences, University of California, Riverside, CA 92521, USA
- Published online on: July 17, 2020 https://doi.org/10.3892/or.2020.7696
- Pages: 1771-1771
Copyright : © Ling et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
This article is mentioned in:
Oncol Rep 42: [Related article:] 991-1004, 2019; DOI: 10.3892/or.2019.7231
Subsequently to the publication of this article, one of the corresponding authors, Dr Wei-Di Zhong, has realized that the information presented in the box for correspondence for him was incorrect. Although Dr Zhong is correctly shown as having three affiliation addresses in the paper, the address affiliation listed first on the paper should have been presented as the address for correspondence, not the second one. Therefore, the authors affiliation information should have appeared as follows (changes are highlighted in bold):
Correspondence to: Dr Wei- Di Zhong, Guangdong Provincial Institute of Nephrology, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
Dr Zhong deeply regrets his oversight in this regard, and apologizes for any inconvenience caused.